Boston settles Guidant spat with JNJ and emerges not too dented
This article was originally published in Clinica
Executive Summary
Boston Scientific and Johnson & Johnson have finally buried the hatchet in their longstanding dispute ignited by an intense bidding war for cardiovascular device firm Guidant in late 2005.
You may also be interested in...
Medtechs At The Wheel In New Health Care Landscape
2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.